CoChat
Sign Up
Cited by 204Cardiovascular Disease and AdiposityCardiovascular Function and Risk FactorsAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Adipocyte Fatty Acid–Binding Protein Suppresses Cardiomyocyte Contraction: A New Link Between Obesity and Heart Disease

Lamounier-Zepter, Valéria, Look, Christiane, Alvarez, Julio, Christ, Torsten, Ravens, Ursula, Schunck, Wolf-Hagen, Ehrhart-Bornstein, Monika, Bornstein, Stefan R., Morano, Ingo·2009·Circulation Research
DOI 10.1161/circresaha.109.200501
Open this paper in CoChat — free account

Abstract

RATIONALE: Adipocyte fatty acid-binding protein (FABP4) is a member of the intracellular lipid-binding protein family and is predominantly expressed in adipose tissue. Emerging evidence suggests that FABP4 plays a role in some aspects of the metabolic syndrome including the development of type 2 diabetes and atherosclerosis. We have recently reported that secretory products from human adipocytes directly and acutely depressed cardiac contractile function. OBJECTIVE: The purpose of this study was to identify this adipocyte-derived cardiodepressant factor. METHODS AND RESULTS: Through mass spectrometry and immunoblotting, we have identified this cardiodepressant factor as FABP4. FABP4 represents 1.8% to 8.1% of total protein secreted by adipocytes in extracellular medium. FABP4 acutely depressed shortening amplitude as well as intracellular systolic peak Ca(2+) in a dose-dependent manner in isolated rat cardiomyocytes. Heart-specific FABP isoform (FABP3) revealed a similar cardiodepressant effect. The N-terminal amino acids 1 to 20 of FABP4 could be identified as the most effective cardiodepressive domain. We could exclude any effect of FABP4 on action potential duration and L-type Ca(2+) current, suggesting a reduced excitation-contraction gain caused by FABP4 as the main inhibitory mechanism. CONCLUSION: We conclude that the release of FABP4 from adipocytes may be involved in the development of cardiac contractile dysfunction of obese subjects.

Overview

Integrity signals

Registry

Crossref · 10.1161/circresaha.109.200501

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Research works printed but not linked: 1

  1. 10.1161/circ.104.6.688 · DOI

Cited by

Sorted by citations

See all 204

Related

See all

Metadata

Authors
Lamounier-Zepter, V., Look, C., Alvarez, J., Christ, T., Ravens, U., Schunck, W.-H., Ehrhart-Bornstein, M., Bornstein, S. R., & Morano, I.
Affiliations
  • From the Medical Clinic III (V.L.-Z., C.L., M.E.-B., S.R.B.), Dresden University of Technology, Germany; Institute of Cardiology (J.A.), La Habana, Cuba; Department of Pharmacology and Toxicology (T.C., U.R.), Dresden University of Technology, Germany; Max-Delbrueck-Center for Molecular Medicine (W.-H.S., I.M.), Berlin-Buch, Germany; and University Medicine Charité (I.M.), Berlin, Germany.
  • Max Delbrück Center (DE)
ORCID
Venue
Circulation Research
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2009-08-14
Volume
105
Issue
4
Pages
326-334
ISSN
  • 0009-7330 (ISSN-L)
  • 1524-4571
DOI
10.1161/circresaha.109.200501
OpenAlex
W2169507034
Cited by
203
References
32
Citations by year
2026: 2 · 2025: 12 · 2024: 15 · 2023: 8 · 2022: 5 · 2021: 13 · 2020: 11 · 2019: 12 · 2018: 7 · 2017: 13 · 2016: 16 · 2015: 14 · 2014: 16 · 2013: 21 · 2012: 15
FWCI
7.99
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation Research (publishedVersion)
  • PubMed (publishedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
  • Site cant be reached (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
adipocyte fatty acid-binding protein, FABP4, FABP3, cardiomyocyte contraction, cardiac contractile dysfunction, adipocyte secretome, excitation-contraction coupling, intracellular calcium, obesity, metabolic syndrome
MeSH terms
Action Potentials, Adult, Aged, Animals, Calcium, Cells, Cultured, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Myocardial Contraction, Obesity, Rats, Wistar, Adipocytes, Calcium Signaling, Metabolic Syndrome, Myocytes, Cardiac, Atherosclerosis, Fatty Acid-Binding Proteins, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review